A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors.

KO-947 - Kura Oncology, Araxes Pharma

http://www.ncbi.nlm.nih.gov/pubmed/39985888

A A Adjei; A J Olszanski; A M Schram; B Tomkinson; E Garralda; J H Francis; J M Ahsan; M Kurman; M Vieito; V Boni

Feb 23, 2025